Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 3
1951 5
1954 1
1955 2
1957 4
1958 1
1959 2
1961 1
1962 1
1963 1
1965 1
1967 1
1973 1
1975 3
1976 10
1977 4
1978 9
1979 8
1980 8
1981 4
1982 6
1983 4
1984 9
1985 6
1986 4
1987 5
1988 18
1989 9
1990 5
1991 9
1992 4
1993 11
1994 2
1995 6
1996 3
1997 4
1998 3
1999 7
2000 10
2001 10
2002 12
2003 19
2004 18
2005 21
2006 24
2007 28
2008 33
2009 33
2010 29
2011 27
2012 34
2013 49
2014 62
2015 58
2016 42
2017 38
2018 35
2019 46
2020 56
2021 70
2022 71
2023 44
2024 57
2025 57

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,065 results

Results by year

Filters applied: . Clear all
Page 1
Rethinking breast cancer follow-up based on individual risk and recurrence management.
De Rose F, Meduri B, De Santis MC, Ferro A, Marino L, Colciago RR, Gregucci F, Vanoni V, Apolone G, Di Cosimo S, Delaloge S, Cortes J, Curigliano G. De Rose F, et al. Among authors: ferro a. Cancer Treat Rev. 2022 Sep;109:102434. doi: 10.1016/j.ctrv.2022.102434. Epub 2022 Jul 1. Cancer Treat Rev. 2022. PMID: 35933845 Free article. Review.
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT. Marinelli D, et al. Among authors: ferro a. J Thorac Oncol. 2025 Mar;20(3):285-295. doi: 10.1016/j.jtho.2024.09.1443. Epub 2024 Oct 9. J Thorac Oncol. 2025. PMID: 39389220
Adverse drug reactions.
Rieder M, Ferro A. Rieder M, et al. Among authors: ferro a. Br J Clin Pharmacol. 2015 Oct;80(4):613-4. doi: 10.1111/bcp.12695. Epub 2015 Sep 20. Br J Clin Pharmacol. 2015. PMID: 26388499 Free PMC article. No abstract available.
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies.
Ferro A, Marinato GM, Mulargiu C, Marino M, Pasello G, Guarneri V, Bonanno L. Ferro A, et al. Crit Rev Oncol Hematol. 2024 Apr;196:104295. doi: 10.1016/j.critrevonc.2024.104295. Epub 2024 Feb 20. Crit Rev Oncol Hematol. 2024. PMID: 38382773 Free article. Review.
Executive Functions in panic disorder: A mini-review.
Giomi S, Siri F, Ferro A, Moltrasio C, Ariyo M, Delvecchio G, Brambilla P. Giomi S, et al. Among authors: ferro a. J Affect Disord. 2021 Jun 1;288:107-113. doi: 10.1016/j.jad.2021.03.084. Epub 2021 Apr 3. J Affect Disord. 2021. PMID: 33848752 Review.
Infectious disease transmission from bioaerosols.
Erath BD, Ferro AR. Erath BD, et al. Among authors: ferro ar. J Expo Sci Environ Epidemiol. 2022 Sep;32(5):645-646. doi: 10.1038/s41370-022-00476-z. Epub 2022 Sep 12. J Expo Sci Environ Epidemiol. 2022. PMID: 36097166 Free PMC article. No abstract available.
PHENSIM: Phenotype Simulator.
Alaimo S, Rapicavoli RV, Marceca GP, La Ferlita A, Serebrennikova OB, Tsichlis PN, Mishra B, Pulvirenti A, Ferro A. Alaimo S, et al. Among authors: ferro a. PLoS Comput Biol. 2021 Jun 24;17(6):e1009069. doi: 10.1371/journal.pcbi.1009069. eCollection 2021 Jun. PLoS Comput Biol. 2021. PMID: 34166365 Free PMC article.
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project.
Gori S, De Rose F, Ferro A, Fabi A, Angiolini C, Azzarello G, Cancian M, Cinquini M, Arecco L, Aristei C, Bernardi D, Biganzoli L, Cariello A, Cortesi L, Cretella E, Criscitiello C, De Giorgi U, Carmen De Santis M, Deledda G, Dessena M, Donati S, Dri A, Ferretti G, Foglietta J, Franceschini D, Franco P, Schirone A, Generali D, Gianni L, Giordani S, Grandi G, Cristina Leonardi M, Magno S, Malorni L, Mantoan C, Martorana F, Meattini I, Meduri B, Merlini L, Miglietta F, Modena A, Nicolis F, Palumbo I, Panizza P, Angela Rovera F, Salvini P, Santoro A, Taffurelli M, Toss A, Tralongo P, Turazza M, Valerio M, Verzè M, Vici P, Zamagni C, Curigliano G, Pappagallo G, Zambelli A; Italian Association of Multidisciplinary Oncology Groups (AIGOM). Gori S, et al. Among authors: ferro a. Cancer Treat Rev. 2024 Dec;131:102832. doi: 10.1016/j.ctrv.2024.102832. Epub 2024 Oct 5. Cancer Treat Rev. 2024. PMID: 39437511 Free article. Review.
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer.
Huffman BM, Rahma OE, Tyan K, Li YY, Giobbie-Hurder A, Schlechter BL, Bockorny B, Manos MP, Cherniack AD, Baginska J, Mariño-Enríquez A, Kao KZ, Maloney AK, Ferro A, Kelland S, Ng K, Singh H, Welsh EL, Pfaff KL, Giannakis M, Rodig SJ, Hodi FS, Cleary JM. Huffman BM, et al. Among authors: ferro a. Cancer Immunol Res. 2025 Jan 9;13(1):9-22. doi: 10.1158/2326-6066.CIR-23-1027. Cancer Immunol Res. 2025. PMID: 39348472 Clinical Trial.
1,065 results